This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Bristol Myers' (BMY) Opdivo Approved for Another Indication
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo gets label expansion in the United States for adjuvant treatment of patients with high-risk urothelial carcinoma.
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
Stock Market News for Aug 5, 2021
by Zacks Equity Research
The Dow and the S&P 500 closed in the red on Wednesday weighed by a lower-than-expected private-sector jobs report and Fed's Vice Chairman Richard Clarida's comment on higher interest rates in 2023 given the current path of economic recovery.
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 22.95% and 9.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust NASDAQ100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQEW
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
by Zacks Equity Research
Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.56% and -2.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance
by Zacks Equity Research
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Moving Average Crossover Alert: Seagen
by Zacks Equity Research
Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Seattle Genetics (SGEN) Down 12.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout
by Zacks Equity Research
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer
by Zacks Equity Research
Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.
Stock Market News for Feb 17, 2021
by Zacks Equity Research
The Dow booked a second straight record high on Tuesday with progress in Biden¿¿¿s $1.9 trillion coronavirus relief package and data showing COVID-19 cases dropping.
Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug
by Zacks Equity Research
The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.
Seattle Genetics (SGEN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
by Zacks Equity Research
Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.